Skip to main content
. 2015 Dec 28;15:1016. doi: 10.1186/s12885-015-2013-3

Fig. 4.

Fig. 4

The proportions of CD28+CD57-, CD28+CD57+, CD28-CD57- and CD28-CD57+ cells from CD8+ T-cells, among lung cancer patients and controls (ad) and according to cancer disease stages (eh), at baseline (T0), 1 month (T1), 3 months (T3), and 6 months (T6)